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Abstract: Aberrant microRNA activity has been reported in many diseases, and studies often find numerous microRNAs   concurrently 
dysregulated. Most target genes have binding sites for multiple microRNAs, and mounting evidence indicates that it is important 
to   consider their combinatorial effect on target gene repression. A recent study associated the coincident loss of expression of six 
microRNAs with metastatic potential in breast cancer. Here, we used a new computational method, miR-AT!, to investigate   combinatorial 
activity among this group of microRNAs. We found that the set of transcripts having multiple target sites for these microRNAs was 
  significantly enriched with genes involved in cellular processes commonly perturbed in metastatic tumors: cell cycle regulation, 
cytoskeleton   organization, and cell adhesion. Network analysis revealed numerous target genes upstream of cyclin D1 and c-Myc, 
indicating that the collective loss of the six microRNAs may have a focal effect on these two key regulatory nodes. A number of genes 
previously   implicated in cancer metastasis are among the predicted combinatorial targets, including TGFB1, ARPC3, and RANKL. 
In summary, our analysis reveals extensive combinatorial interactions that have notable implications for their potential role in breast 
cancer   metastasis and in therapeutic development.
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Introduction
Involved in the regulation of many cellular processes, 
microRNAs are short, endogenous   oligonucleotides 
that  have  been  implicated  in  a  wide  variety  of 
  diseases. The mature form of microRNAs (miRNAs) 
are approximately 22 nucleotides in length and anneal 
to complementary sites in the 3′ untranslated region 
(UTR) of target transcripts as part of an RNA-induced 
silencing complex (RISC). While microRNAs appear 
to  act  through  multiple  mechanisms,  two  general 
modes  of  action  have  been  identified:  transcript 
degradation and inhibition of protein translation.1–3 
The  former  is  associated  with  near-perfect  base 
complementarity  between  a  miRNA  and  its  target 
sequence, while non-perfect miRNA-target matches 
result in inhibition of protein translation. A number 
of recent reports have shown that non-perfect com-
plementarity can also result in mRNA degradation 
through  poly(A)  deadenylation.4,5  Therefore,  the 
effect  of  microRNA  activity  may  be  reflected  by 
changes of either mRNA or protein levels,   depending 
on  the  microRNA  and  target  transcript  involved. 
There  are  currently  over  700  known  miRNAs  in 
the human genome, and each miRNA may regulate 
  dozens to hundreds of target transcripts. Reports have 
shown numerous miRNAs aberrantly expressed in a 
variety  of  diseases,  including  cancer,  and  indicate 
that  hundreds  and  perhaps  thousands  of  transcript 
  targets  could  potentially  be  affected  in  neoplastic 
tissue. The 3′ UTR in a single messenger RNA may 
contain binding sites for a number of microRNAs, 
and  a  transcript  can  be  concurrently  repressed  by 
multiple microRNA species.6 Therefore, the genome-
wide complexity of microRNA interactions presents 
a  formidable  challenge  to  understanding  cellular 
regulation, particularly when assessing the impact of 
multiple dysregulated miRNAs.
Mounting evidence reveals that microRNAs can 
exert a cooperative effect on target gene repression. 
Since  a  gene  product  may  be  simultaneously 
repressed  by  multiple  microRNAs,  and  a  num-
ber of microRNAs may be differentially expressed 
in a given disease   condition, it is essential to con-
sider  their  combinatorial  interactions.1,3,7,8 A  recent 
genome-wide  investigation  demonstrated  a  signifi-
cant  and  positive  correlation  between  the  number 
of microRNA binding sites in a transcript and the 
mRNA decay rate.9 This additive effect is believed 
to be due primarily to the combinatorial contribution 
of   multiple microRNAs since only a small fraction of 
transcripts contain multiple binding sites for any sin-
gle miRNA. The authors noted that the vast majority 
of  target  genes  have  sites  for  multiple  microRNA 
species, thus   providing a mechanism for cooperative 
repression of target genes. Another recent study iden-
tified combinatorial activity among four microRNAs 
involved  in  monocyte  differentiation.10  Concurrent 
over-expression of the four microRNAs resulted in 
numerous  gene  expression  changes  that  were  not 
observed with any one of the four individual miRNA 
transfections, demonstrating cooperative interactions. 
Two microRNAs in a bicistronic cluster (miR-143 
and miR-145) were reported to be repressed in most 
gastric and colon cancer patients that were tested.11 
By  over-expressing  these  microRNAs  in  a  gastric 
cancer cell line, the authors confirmed an additive 
effect on target gene repression, and their observa-
tions  indicate  combinatorial  activity  by  the  two 
microRNAs. A separate study demonstrated that while 
these two microRNAs are nonhomologous, they share 
numerous common targets involved in actin dynam-
ics and cytoskeletal function, suggesting cooperative 
regulation of cellular pathways.12 Based on growing 
evidence  of  cooperative  microRNA  activity,  it  is 
imperative to consider and investigate combinatorial 
effects where multiple dysregulated microRNAs are 
identified in expression profiling studies.
While  several  computational  tools  have  been 
developed to address components of this goal, there is 
a need for freely available software that can perform 
combinatorial  target  analysis  of  microRNAs  and 
functional annotation of the target genes.7,13–16 A recent 
review  on  computational  methods  for  microRNA 
studies  called  for  the  development  of  tools  for 
combinatorial analysis and noted that “it is important 
to develop novel computational methods that explic-
itly capture dependencies between individual miRNA 
targeting and reveal synergistic effects on function-
ally related genes”.17 Here, we introduce a web-based 
bioinformatics  application,  miR-AT!  (microRNA 
Combinatorial Analysis of Targets), which leverages 
and  integrates  several  existing,  high-quality  data-
bases  to  enable  combinatorial  microRNA  target 
characterization and functional analysis. Among the 
features of miR-AT! are: the ability to predict combi-
natorial targets of multiple microRNAs, user specified Combinatorial microRNAs in breast cancer metastasis
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parameters for minimum number of sites and number 
of unique microRNAs found in each target, minimum 
score criteria, integrated functional annotation of pre-
dicted targets, and a novel clustering implementation 
that enables identification of transcripts with similar 
microRNA target site patterns. In this work we have 
applied miR-AT! to investigate combinatorial activ-
ity associated with a set of microRNAs implicated in 
breast cancer metastasis.
Tavazoie et al recently identified six microRNAs 
(hsa-mir-335, 126, 206, 122, 199a-3p, and 489) that 
were significantly decreased in highly metastatic breast 
cancer cell derivatives.18 All six of the microRNAs 
were consistently downregulated in cell derivatives that 
aggressively metastasized to bone or lung, as compared 
to the parental cells. The authors focused on this set of 
miRNAs based on the combined results of microarray 
profiling and RT-PCR, and subsequently investigated 
the effect of each of the six microRNAs by individu-
ally restoring expression with retroviral transduction. It 
was determined that individually, miR-335, miR-206, 
and miR-126 had the greatest effect on metastasis, and 
restoration of either of these microRNAs resulted in 
a significant decrease in lung colonization at the end 
point. Restoration of either of miR-122, miR-199a-3p, 
or miR-489 also decreased colonization, but at earlier 
timepoints.  The  six  microRNAs  reside  on  five  dif-
ferent chromosomes, and there is no evidence of co-
regulation of these microRNAs. The coincident loss 
of all six microRNAs in each of the highly metastatic 
cell  derivatives  suggests  that  cooperative  activity 
among them may be important in maintaining post-
transcriptional regulation of target genes involved in 
tumor growth and metastasis. We have used miR-AT! 
to perform computational target analysis of the aggre-
gate set of six miRNAs, considering potential combi-
natorial activity and multiple microRNA binding sites 
in predicted target genes.
Methods
miR-AT!
miR-AT! is a web accessible application available at 
http://mir-at.org. A user guide is provided through the 
“help” link available at the home page. The application 
leverages several high quality databases and software 
applications to provide target prediction and   subsequent 
functional  annotation  of  target  genes. Additionally, 
miR-AT!  provides  the  capability  to  cluster  target 
genes by the pattern of microRNA binding sites in 
their 3′ UTR.
From a user-submitted list of miRNA identifiers, 
the miR-AT! application scans a local   implementation 
of  the  MicroCosm  Targets  database,  formerly 
known as miRBase Targets (http://microrna.sanger.
ac.uk/targets/v5/).19  The  application  identifies  all 
  transcripts having predicted target sites matching the 
microRNAs provided in the input set and meeting 
user-specified score criteria. Target identification in 
MicroCosm   Targets is accomplished using 3′ UTRs 
of Ensembl transcripts and the miRanda algorithm,20 
allowing no more than one mismatch in the critical 
“seed”  region  on  the  5′  end  of  the  miRNA.  Each 
  target  site  in  the  database  has  an  associated  score 
and P-value. User selectable parameters in miR-AT! 
allow the   specification of a minimum score required 
for each target site and a maximum P-value allowed. 
The  user  can  specify  a  minimum  number  of  total 
  target  sites  required  for  each  transcript,  and  these 
can  be  satisfied  by  any  combination  of  the  input 
microRNAs.    Additionally,  a  minimum  number  of 
unique microRNAs represented in each transcript can 
be specified. miR-AT! currently recognizes miRNA 
identifiers for human, mouse, and rat. Addition model 
organisms will be added in the future.
A  range  of  computational  methods  have  been 
developed  for  microRNA  target  site  prediction, 
but  few  have  included  consideration  of  combi-
natorial  effects.  Of  established  methods,  perhaps 
the two most closely aligned with our objective of 
investigating  microRNA  combinatorial  activity  are 
miRGator  and  microRNA.org.15,21  Both  methods 
allow for the input of multiple microRNAs, and both 
report    targets  having  one  or  more  predicted  sites 
associated with the input microRNA set. However, 
miR-AT!  provides  additional  capabilities  essential 
to investigating   combinatorial effects, including the 
ability to   specify a minimum number of target sites 
per gene, a minimum number of unique microRNAs 
from the input set that must target each gene, and 
filtering  tools  for  individual  target  site  scores  and 
P-values.  Furthermore,  miRGator  restricts  queries 
to fewer than five microRNAs, and microRNA.org 
is limited to searches for targets of one or all of the 
input  microRNAs,  not  intermediate  combinations. 
Collectively,  miR-AT!  provides  greater  flexibility 
to construct combinatorial queries and enables the dombkowski et al
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selection and filtering of high quality targets based 
on site number, score, and significance. Additionally, 
the target score distribution analysis tool available in 
miR-AT! allows the user to visualize a histogram of 
scores associated with the target gene set, thus provid-
ing assistance in identifying cutoff scores to remove 
low confidence target predictions.
In addition to the identification of combinatorial 
target  gene  sets,  an  important  feature  of  miR-AT! 
is the ability to submit the target sets to DAVID for 
comprehensive  functional  annotation  and  pathway 
analysis. MirGator and microRNA.org do not provide 
functional annotation capability for combinations of 
microRNAs. Another unique feature of miR-AT! is 
the ability to cluster target genes based on the combi-
natorial pattern of target sites found in each 3′ UTR. 
This feature identifies groups of genes that have simi-
lar target site combinations and thus are predicted to 
be under similar influence of the input microRNAs. 
The method also clusters the input microRNAs based 
on their target site patterns in the identified target 
gene set. The clustering tool can be used to explore 
the  predicted  combinatorial  effect  of  microRNAs 
on sub-clusters of target genes and also to identify 
microRNAs having potential cooperative activity as 
discussed below and exemplified by our findings with 
miR-122 and miR-206.
In  this  work  we  submitted  six  microRNAs 
  previously identified as repressed in highly   metastatic 
breast  cancer  cells:  hsa-miRs  335,  126,  206, 
122,  199a-3p,  and  489.  We  used  the  synonymous 
  designations of hsa-mir-199a-3p and hsa-mir-122 for 
199a* and 122a respectively, the latter having been 
used in the Tavazoie report.
Target list output
Each  target  with  a  miRNA  site  satisfying  the 
specified selection criteria is included in the output 
list of   transcripts. miR-AT! calculates a cumulative 
score for each transcript, derived from the sum of 
all miRNAs meeting the specified selection criteria. 
The cumulative score provides for the identification 
of transcripts most likely affected by the combined 
set of input miRNAs. Multiple bound miRNAs can 
additively  affect  messenger  RNA  translation  and/
or stability, thus it is crucial to consider the cumu-
lative set of miRNA sites when assessing putative 
targets. By default, the output list is sorted by the 
cumulative score. Thus, targets with multiple, high 
scoring sites will be found towards the top of the list 
and transcripts with a lower cumulative score will 
be found towards the bottom. For each target in the 
output  list  the  NCBI  Gene  ID,  Ensembl  gene  and 
transcript    identifiers,  description,  number  of  target 
sites, and cumulative score are provided. The NCBI 
and Ensembl IDs are hyperlinked to the respective 
databases to provide extensive information for each 
target transcript. The total number of miRNA sites sat-
isfying the selection criteria is provided for each tran-
script. Clicking on this value generates an   additional 
panel that provides the chromosomal location of each 
site  along  with  the  associated  miRanda  score  and 
P-value. The   target site panel also provides a list of 
all known miRNAs that target the selected transcript. 
The list of transcripts generated by miR-AT! can be 
sorted by either the cumulative score (default) or by 
using any of the other data columns, eg, gene name. 
The target list can be saved as a tab delimited text 
file. An additional feature of miR-AT! is the ability to 
generate histograms of target site score distributions. 
Histograms are provided for both individual scores 
and cumulative scores.
Functional analysis of identified targets
Microarray  experiments  often  produce  lengthy 
lists  of  differentially  expressed  genes.  During  the 
maturation  of  microarray  technology  it  became 
apparent that such lists require computational tools 
that can identify biological processes and pathways 
that  are  associated  with  the  genes  in  a  given  list. 
We have integrated miR-AT! with one of the most 
widely utilized and cited tools that belong to this 
class  of  bioinformatics  resources:  DAVID  (Data-
base  for  Annotation,  Visuali  zation  and  Integrated 
Discovery).22 DAVID allows for the rapid identifica-
tion of enriched gene ontologies and biological path-
ways associated with a given gene list, and it also 
provides comprehensive functional annotation drawn 
from  numerous  biological  databases.  Among  the 
resources available through DAVID are KEGG and 
Biocarta pathways. An output list of target genes in 
miR-AT! can be automatically submitted to DAVID 
by  simply  clicking  the  “Functional  Annotation” 
button at the top of the output list. The automated Combinatorial microRNAs in breast cancer metastasis
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miR-AT! procedure utilizes NCBI Entrez Gene IDs 
for submission to DAVID, and a new browser window 
will appear with DAVID results. Users are encouraged 
to explore the extensive help available at the DAVID 
web  site  (http://david.abcc.ncifcrf.gov/).  Functional 
annotation  clustering  performed  in  this  work  was 
accomplished using the default   settings of DAVID 
version 6.7. Ontology analysis utilized the GO_BP_
FAT  records  within  DAVID,  and  the  conservative 
EASE P-values were used.
hierarchical clustering
To facilitate the identification of transcripts with similar 
microRNA target site patterns, we   developed a novel 
adaptation of hierarchical clustering within miR-AT!. 
We integrated Java Treeview and Cluster 3.0 software 
libraries within the miR-AT! application.23,24  After using 
miR-AT! to identify predicted transcripts for a set of 
input microRNAs the user can press the “Clustering” 
button at the top of the page to produce a hierarchi-
cal clustering result. Predicted transcripts with similar 
patterns of target sites, considering the input microR-
NAs, are clustered together. Quantitative values used 
in the clustering are derived from the scores of each 
microRNA/transcript  combination.  The  clustering 
distance between two transcripts is determined by the 
correlation of microRNA target site scores in their 3′ 
UTRs.   Additionally, microRNAs are clustered based 
on their target site patterns among all of the predicted 
targets, thus allowing for two-dimensional clustering. 
The  clustering  implementation  in  miR-AT!  allows 
for  the  selection  of  a  variety  of  distance  metrics. 
The Spearman correlation distance metric was used 
in this work.
Analysis of signaling networks
To  identify  key  nodes  in  signaling  networks 
  downstream  of  genes  targeted  by  the  collective 
group  of  microRNAs  we  utilized  the  ExPlain  3.0 
analysis system (http://biobase-international.com/).25 
This application requires a license and therefore is 
not integrated within miR-AT!. The key node analysis 
algorithm in the ExPlain system identifies downstream 
molecules that are connected to a maximal number 
of input molecules, within a specified distance. The 
default parameter settings and false discovery rate 
(FDR) computation were used.
Results
We used miR-AT! to predict the aggregate activity of 
six microRNAs that were repressed in metastatic breast 
cancer cells (hsa-mir-335, 126, 206, 122, 199a-3p, and 
489) in the Tavazoie et al study. Focusing on target 
genes with multiple miRNA binding sites, we used the 
selectable parameters available in miR-AT! to iden-
tify transcripts having at least two miRNA binding 
sites  representing  at  least  two  unique  microRNAs 
from the input set. To avoid sites with low prediction 
confidence, we required each miRNA binding site to 
have a minimum MicroCosm score of 15. Analysis of 
nearly 900,000 target scores in MicroCosm revealed 
a  near-normal  distribution  with  a  mean  score  of 
16.398 and a standard deviation of 0.883 (data not 
shown).  Based  on  the  score  distribution,  a  cutoff 
score of 15 eliminates the lowest 5% of scores from 
the MicroCosm database. Using miR-AT! with these 
parameter  settings  we  identified  529  genes    having 
multiple target sites of the six miRNAs. The list of 
transcripts  is  provided  in  Supplementary  Table  1, 
ranked  by  cumulative  score.  One  target  transcript 
had six miRNA sites, four transcripts had five sites, 
18 had four sites, 89 had three sites, and 417 had 
two sites. The cumulative scores for each transcript 
ranged from 30.4 to 95.1.
Predicted targets that have previously 
been confirmed
Among  the  list  of  combinatorial  targets  predicted 
by miR-AT! are genes associated with proliferation 
and  metastasis  and  for  which  post-  transcriptional 
regulation by at least one of the predicted microRNA 
interactions  has  previously  been  confirmed.  Our 
combinatorial  target  analysis  identified    Aldolase 
A  (ALDOA)  as  a  putative  target  of  miR-122  and 
miR-489. ALDOA is one of three aldolase isozymes 
which  play  a  role  in  glucose  metabolism.  The 
dependency  of  proliferating  tumors  on    elevated 
levels  of  glucose  metabolism  has  been  known  for 
many  years,  and  increased  levels  of  aldolase  in 
  malignancies was first   identified in 1953.26,27 Since 
then, numerous   publications have reported elevated 
levels of ALDOA in a variety of cancers,   including 
breast,    hepatocellular,  and  lung.28–32  Increased 
  levels  of ALDOA  have  also  been  associated  with 
invasiveness and metastasis.33,34   Consistent with the dombkowski et al
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prediction obtained through miR-AT!, several labs 
have   verified that ALDOA is a target of mir-122, and 
miR-122 expression results in a reduction of ALDOA 
mRNA levels.35–37 Our analysis indicates that miR-
122 and miR-489 may cooperatively provide post-
transcriptional regulation of Aldolase A and that their 
combined  loss  may  contribute  to  dysregulation  of 
Aldolase A expression.
General  transcription  factor  2B  (GTF2B)  is 
the  third  highest  scoring  target  transcript  of  the 
collective group of six microRNAs. It is predicted 
by miR-AT! to be a target of microRNAs miR-122 
(two  sites),  miR-126,  miR-199a-3p,  and  miR-206, 
for a total of five sites. Validation of GTF2B regu-
lation  at  the  mRNA  level  by  miR-122  has  been 
reported in rat hepatocytes.36 Since GTF2B is a ubiq-
uitous transcription factor involved in the regulation 
of many genes, concurrent repression of these four 
microRNAs could have extensive secondary effects 
on gene regulation.38
Functional annotation of the cumulative 
target gene set
We  sought  to  identify  genes  associated  with   
metastasis  and  proliferation  from  among  the 
transcripts  targeted  by  the  collective  set  of  the   
six miRNAs. An important feature of miR-AT! is 
the ability to seamlessly submit target gene lists to 
DAVID  for  functional  annotation  and  analysis  of 
enriched biological processes and pathways. The set 
of 529 genes identified with multiple target sites of 
the six miRNAs was submitted to DAVID for func-
tional  annotation  using  the  automated  hyperlink 
available in miR-AT!. Default DAVID settings were 
used. Of the input set, 414 genes were recognized 
in the DAVID database. Within DAVID we selected 
gene ontology biological process (GOTERM_BP_
FAT) to identify cellular processes associated with 
the genes targeted by the six microRNAs.
Several biological processes pertinent to prolif-
eration and metastasis were flagged as statistically 
  significant  in  the  DAVID  analysis,  based  on  the 
number of target genes belonging to each category 
and compared to the number of genes in the given 
category found throughout the genome. Among the 
significant  ontologies  were  cell  cycle  checkpoint 
(P = 0.0054) and negative regulation of cell adhe-
sion (P = 0.018). Table 1 lists target genes associated 
with these categories and the microRNAs that target 
each gene.
Among the 529 predicted targets, five genes are 
involved  in  negative  regulation  of  cell  adhesion. 
Table 1. enriched biological processes among the 529 target genes having multiple microRNA binding sites.
entrez  
ID
Gene  
symbol
Gene name number of microRnA sites
miR- 
335
miR- 
126
miR- 
206
miR- 
122
miR- 
199a-3p
miR- 
489
cell cycle checkpoint (P = 0.0054, 3.8-fold enrichment)
51499 TRIAP1 TP53 regulated inhibitor of  
apoptosis 1
1 1
7272 TTK TTK protein kinase 1 1
1029 CdKN2A Cyclin-dependent kinase inhibitor 2A 1 1
60561 RINT1 RAd50 interactor 1 1 1
8525 dgKZ diacylglycerol kinase, zeta 104kdA 1 1
56984 PSMg2 Proteasome assembly chaperone 2 1 1
11200 CheK2 ChK2 checkpoint homolog 1 1
7040 TgFB1 Transforming growth factor, beta 1 1 1
negative regulation of cell adhesion (P = 0.018, 5-fold enrichment)
7045 TgFBI Transforming growth factor,  
beta-induced, 68kdA
1 1
1029 CdKN2A Cyclin-dependent kinase inhibitor 2A 1 1
5921 RASA1 RAS P21 protein activator  
(gTPASe activating protein) 1
1 1
395 ARhgAP6 Rho gTPASe activiating protein 6 1 2
7040 TgFB1 transforming growth factor, beta 1 1 1Combinatorial microRNAs in breast cancer metastasis
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Compared  to  the  number  of  genes  in  the  human 
genome that belong to this ontology, the frequency 
of occurrence in the target gene set represents 5-fold 
enrichment, as calculated in the DAVID functional 
annotation  analysis.  Several  of  these  genes  have 
been  implicated  in  metastasis.  TGFBI  (transform-
ing growth factor, beta-induced, 68kDA) is a gene 
that codes for an extracellular matrix (ECM) protein 
involved in cell adhesion and migration. Our results 
indicate  that  the  3′  UTR  of  TGFBI  contains  pre-
dicted binding sites for miRs 122 and 489, and that 
a decrease in expression of these two microRNAs 
may result in increased expression of TGFBI protein. 
Elevated expression of TGFBI has been associated 
with the progression and metastatic spread of human 
pancreatic  cancer  and  hepatoma  cells.39,40  Overex-
pression of TGFBI was demonstrated to significantly 
increase metastatic potential by promoting extrava-
sation in colon cancer cells.41 TGFBI has also been 
associated with metastasis of esophageal squamous 
cell carcinoma.42
The biological process with the greatest statistical 
significance was cell cycle checkpoint (P = 0.0054). 
This category included eight genes from the set of 
529  predicted  targets  and  was  enriched  3.8-fold, 
  compared to the overall genome. A predicted   target 
gene  associated  with  metastasis  and  involved  in 
both cell cycle checkpoint and negative regulation 
of  cell  adhesion  is  TGFB1  (transforming  growth 
factor, beta1). This gene has two high-scoring target 
sites for miRs-122 and 199a-3p. While TGB1 inhib-
its early stage tumorigenesis, it promotes invasion 
and  metastasis  in  later  stages  of  the  disease.43,44 
Elevated  plasma  levels  of  TGFB1  are  correlated 
with decreased survival in metastatic breast cancer 
patients.45  In  a  mouse  xenograft  model  using 
metastatic  MDA-MB-435  cells,  knockdown  of 
TGFB1 using siRNA resulted in a 90% decrease in 
the number of macroscopic lung metastases.46 The 
potential role of these two microRNAs in TGFB1 
regulation warrants further investigation.
Interestingly,  three  transcripts  associated  with 
cell cycle checkpoint each have target sites for both 
miRs 335 and 489: TTK, TRIAP1, and RINT1. TTK 
is a dual-specificity kinase involved in centrosome 
  duplication. Expression of TTK has been associated 
with cell proliferation.47 Excessive   accumulation of 
TTK protein was linked to the production of extra 
centrosomes during mitosis and may lead to genomic 
instability  and  tumorigenesis.48  Dramatically 
increased TTK mRNA levels were found in   genetically 
unstable breast cancer cell lines and in high-grade 
primary  breast  cancer  tissue.49  Over-expression  of 
TRIAP1 (Tp53 regulated inhibitor of apoptosis) has 
been reported to inhibit apoptosis induced by DNA 
damage,50 and elevated levels of TRIAP1 were found 
in greater than 50% of multiple myeloma cases.51 Our 
results indicate that concurrent loss of miRs 335 and 
489 may result in dysregulation of this group of genes 
involved in cell cycle regulation.
Evaluation of statistical significance
We have relied on the established statistical model 
in  DAVID  to  identify  biological  processes  that 
are  enriched  with  genes  from  the  target  gene  set. 
The  P-  values  provided  by  DAVID  are  derived 
using a modified Fisher exact test. The test deter-
mines if the proportion of genes from the target set 
  belonging to a given gene ontology is significantly 
  different than the proportion of genes from the over-
all  genome  belonging  to  the  same  ontology.  The 
DAVID  implementation  of  the  Fisher  Exact  test 
(EASE score) subtracts one from the number of genes 
in an ontology category prior to calculating the sig-
nificance, and is therefore more conservative than the 
standard Fisher test. To   further assess the robustness 
of DAVID scores applied to microRNA target sets we 
sought to determine if the biological processes identi-
fied in our analysis of the six Tavazoie microRNAs 
would arise by chance when using randomly selected 
groups  of  microRNAs.  We  performed  a  bootstrap 
analysis with 100 trial sets, each comprised of six 
microRNAs randomly drawn from the MicroCosm 
database. For each trial the predicted target   transcripts 
were identified with miR-AT! using the same param-
eter  settings  specified  above,  and  the  number  of 
target genes associated with each gene ontology or 
biological process was tabulated. We then calculated 
an empirical P-value that represents the probability 
that  the  number  of  genes  associated  with  a  given 
ontology from the Tavazoie target set would occur by 
chance. The bootstrap P-value was obtained using pb 
= r/t where t is the total number of trials, and r is the 
  number of trials that produced a gene count equivalent dombkowski et al
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or greater to that obtained with the Tavazoie micro-
RNAs for the given biological process.
We had previously noted that cell cycle   checkpoint 
and negative regulation of cell adhesion are among 
the  statistically  significant  ontologies  identified 
by  DAVID  analysis  of  the  529  predicted  targets 
of  the  six  Tavazoie  microRNAs  (detailed  above). 
From this target set, eight genes belong to the cell 
cycle    checkpoint  category,  with  a  corresponding 
DAVID P-value of 0.0054. Of the 100 bootstrap tri-
als the greatest number of target genes found in this 
  category  was  five,    providing  a  bootstrap  P-value 
of  zero.  For  the    negative  regulation  of  cell  adhe-
sion category five genes were originally identified 
among  the  529    predicted  targets,  with  a  DAVID 
P-value of 0.018. Again, none of the bootstrap   trials 
produced  an    equivalent  or  greater  number  of  tar-
get genes for this ontology. Our bootstrap analysis 
clearly   demonstrates that the number of genes from 
the  Tavazoie  set    belonging  to  these  ontologies  is 
  statistically significant and highly unlikely to have 
occurred by chance.
Using the statistical results obtained for all gene 
ontologies where more than one gene was   identified 
from  the  Tavazoie  target  set,  Figure  1  provides  a 
comparison of the P-values from DAVID enrichment 
analysis to those derived from our bootstrap   analysis. 
Each data point represents one gene   ontology, and a 
clear trend is evident. For 96% of ontologies the DAVID 
P-value is greater than that obtained empirically with 
our bootstrap analysis, revealing that the DAVID val-
ues are indeed conservative and often underestimate 
significance of enrichment for microRNA target sets. 
We recognize that the bootstrap approach may offer 
greater statistical power, and implementation of this 
method within miR-AT! would be of value. However, 
the computational requirements necessary to accom-
plish bootstrap analysis for any possible combination 
of parameter settings and input microRNA set size 
precludes implementation at this time. We hope to 
offer this feature in a subsequent release of the soft-
ware, but our results demonstrate that the enrichment 
P-values available through DAVID are reliable and 
generally underestimate significance.
Cyclin d1 and c-Myc are key nodes 
downstream of the cumulative set 
of genes targeted by the repressed 
microRNAs
To detect central signaling nodes that may be focal 
points of dysregulation due to the collective loss of 
the six microRNAs, we identified converging   signal 
transduction pathways downstream of the 529 pre-
dicted  target  genes. We  used  the  key  node  search 
algorithm of the ExPlain 3.0 system (Biobase GmbH) 
to perform the analysis.25 This application requires a 
license and therefore is not integrated within miR-AT!. 
The ExPlain method explores cell signaling networks 
within a specified range from each input molecule 
(gene/protein) to find the most proximal molecule hav-
ing the maximal number of connections to the overall 
set of input molecules. Since the resulting score may 
be influenced by the level of connectivity of each mol-
ecule, the total number of connections for each node 
is taken into account by the algorithm. Using the 529 
predicted target genes as the input set and searching 
for key downstream nodes, the two highest scoring 
nodes were c-Myc and cyclin D1 (CCND1). c-Myc is 
downstream of 37 target transcripts and cyclin D1 is 
downstream of 36 target transcripts. The probability 
that these key nodes would achieve their scores by 
chance (false discovery rate) is 0.04 for c-Myc and 
0.076 for cyclin D1. Figure 2 shows the network of 
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Figure 1. Comparison of enrichment P-values obtained from dAVId with 
those derived using bootstrap analysis for 900 gene ontologies.   Bootstrap 
P-values were calculated from 100 trials using randomly selected sets 
of  six  microRNAs  each.  For  each  trial,  target  genes  were  predicted 
using miR-AT!, and the number of genes in each ontology category was 
  tabulated. The bootstrap P-value represents the probability that random 
trials would produce an equivalent or greater number of genes for a given 
ontology than that obtained from the Tavazoie target set. dAVId P-values 
were obtained using default functional annotation settings in dAVId. The 
dAVId  P-values  consistently  underestimate  statistical  significance  of 
ontology enrichment for the microRNA target set.Combinatorial microRNAs in breast cancer metastasis
Cancer Informatics 2011:10  21
target genes upstream of c-Myc and cyclin D1. Blue 
color indicates genes that are predicted targets of the 
six microRNAs. Supplementary Table 2 provides a 
list of the associated target genes.
Amplification and over-expression of cyclin D1 
and c-Myc are widely known to contribute to onco-
genesis in a variety of tumors, including breast cancer, 
and is associated with decreased patient survival.52–57 
A study using a mouse model of breast tumorigenesis 
demonstrated a synergistic interaction in response to 
concurrent over-expression of cyclin D1 and c-Myc, 
resulting  in  cells  that  were  highly  invasive  and 
metastatic.58  Our  computational  analysis  indicates 
that  numerous  genes  targeted  by  the  six  repressed 
microRNAs are involved in signaling networks that 
converge  upon  cyclin  D1  and  c-Myc,  potentially 
  contributing in a focal manner to their dysregulation.
Clustering of transcripts  
by microRNAs target site patterns
As  noted  above,  several  target  genes  associated 
with cell cycle checkpoint each have target sites for 
both miRs 335 and 489. This observation raised the 
question  as  to  whether  some  biological  processes 
are under greater influence of specific combinations 
of  microRNAs.  To  further  explore  combinatorial 
patterns of microRNA regulation in the cumulative 
set of target genes we implemented a novel adaptation 
of a clustering method frequently used in microar-
ray gene expression analysis. Hierarchical clustering 
is widely used to identify subsets of genes having 
similar  expression  profiles  when  measured  over  a 
series of biological samples.59 This method is also 
commonly used to cluster biological samples that are 
similar based on gene activity assayed in a microarray 
experiment. Here, we utilized hierarchical clustering 
to identify clusters of target genes based on similarity 
of predicted microRNA target site patterns in their 
3′ UTRs. For each of the 529 target transcripts, the 
total MicroCosm score of predicted target sites was 
tabulated individually for each of the six microRNAs. 
Transcripts  with  similar  target  site  patterns  were 
clustered  together.  Transcripts  are  represented  as 
rows in our clustering results. This approach enabled 
us  to  identify  clusters  of  genes  that  are  similarly 
regulated by the six Tavazoie microRNAs, based on 
Key
c-myc cyclin D1
Figure 2. Cyclin d1 and c-Myc are key nodes downstream of the collective set of genes targeted by the six microRNAs. Analysis of convergent signaling 
pathways downstream of the 529 predicted target genes was performed using the key node algorithm of the exPlain Analysis System (Biobase). Blue 
indicates transcripts that are predicted targets of two or more of the six repressed microRNAs. 37 targeted transcripts converge upon c-Myc and 36 
  converge upon cyclin d1, with some transcripts common to the two paths. Target genes are listed in Supplementary Table 2.dombkowski et al
22  Cancer Informatics 2011:10
computational prediction of target sites. Additionally, 
we clustered the six microRNAs based on the target 
site  tabulation,  grouping  together  microRNAs  that 
tend to co-occur within the same transcripts, as indi-
cated by the columns in the clustering result.
The  clustering  result  is  shown  in  Figure  3, 
where rows represent the 529 target transcripts and 
  columns represent the six microRNAs. The block 
representing each row-column intersection is col-
ored to indicate the total score of target sites pre-
dicted within the transcript 3′ UTR for the given 
microRNA.  Blue  indicates  no  target  site  present, 
and  red  indicates  a  predicted  target  site. The  red 
color intensity represents the cumulative score for 
all sites of the specified target-microRNA combi-
nation, with more intense color indicating a higher 
individual site score or multiple sites for the given 
microRNA.  The  dendrogram  above  the  columns 
reveals  that  miR-122  and  miR-206  are  clustered 
together and is the most similar pair of microRNAs 
due to the coexistence of their sites in large number 
of target genes. The hierarchical clustering result 
shows that this group of transcripts is by far the 
largest sub-cluster associated with a pairwise com-
bination of microRNAs.
We  then  used  miR-AT!  to  tabulate  target  genes 
having  both  sites  for  each  pairwise  microRNA 
combination. The results are summarized in Figure 4 
and reveals that there are 174 transcripts having both 
miR-122 and miR-206 sites. This microRNA target site 
pair is found in nearly three times as many transcripts 
as the next most frequent pair of microRNAs. Inspec-
tion  of  the  mature  sequences  for  miRs  122  and 
206 reveals that their seed regions are nearly identical; 
therefore, target sites for these two microRNAs tend to 
co-occur in the 3′ UTR. An alignment of microRNAs 
122 and 206 was performed using the R-coffee algo-
rithm which is suited for aligning non-coding RNA 
sequences (http://www.tcoffee.org).60 The alignment 
result  shown  in  Figure  5  highlights  the  similarity 
between these two microRNAs. The seed region at 
the 5′ end of a microRNA is critical to its activity, and 
hybridization to a target transcript is greatly depen-
dent on near-perfect base-pairing within this region.61 
The eight base seed region of miRs 206 and 122 are 
identical with the exception of a single base difference 
which introduces an allowable G:U wobble. The G:U 
base pair occurs widely in RNA secondary structure.62 
A number of confirmed miRNA target sites have been 
identified with G:U base pairs in the seed region, and 
it has been demonstrated that a G:U base pair can be 
tolerated within a 7mer or 8mer seed, albeit with some 
reduction in regulatory efficiency.6,61 The similarity of 
miRs 122 and 206 actually extends through the first ten 
nucleotides at the 5′ end, with a second G:U w  obble 
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Figure 3. hierarchical clustering of transcripts based on microRNA   target 
site patterns. Red intensity reflects the total score of predicted sites for 
each  microRNA/transcript  combination.  Brighter  intensity  indicates 
multiple target sites for a microRNA within a given transcript or a high 
scoring individual site. Blue indicates no predicted target site. Transcripts 
targeted by the miR-122/206 pair are enriched for genes associated with 
cytoskeleton organization and cell-matrix adhesion. Transcripts targeted 
by the miR-489/335 pair are enriched for genes associated with cell cycle 
control.Combinatorial microRNAs in breast cancer metastasis
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found in the ninth position. These microRNAs are thus 
predicted to target an overlapping set of transcripts 
which would be dependent on the additive abundance 
of the two miRs. Based on our analysis, we propose 
that these two microRNAs could potentially act in a 
concerted and failsafe manner for many target genes, 
where the partial loss of one of the microRNAs might 
be compensated by the other microRNA in the pair. A 
loss of both microRNAs, as observed in the Tavazoie 
work,  would  result  in  extensive  dysregulation  of 
numerous target genes.
We applied miR-AT! and the integrated DAVID 
analysis to examine enrichment of biological processes 
associated with sets of genes targeted by pairwise com-
binations of the six microRNAs, which are reflected 
as subclusters in Figure 3. For the target gene set of 
each pairwise microRNA combination we identified 
enriched Gene Ontology Consortium biological pro-
cess categories using the default statistical cutoff in 
DAVID  and  further  filtering  to  identify  categories 
with a minimum 2-fold enrichment. We found that 
the 174 transcripts targeted by both miRs 206 and 
122  are  enriched  5-fold  for  genes  associated  with 
  regulation of cytoskeleton organization (P = 0.016) 
and 6-fold for cell matrix adhesion (P = 0.026). The 
50 transcripts targeted by both miR-335 and miR-489 
are 15-fold enriched with genes involved in cell cycle 
checkpoint (P = 0.016). The enriched sub-clusters are 
indicated in Figure 3.
Remodeling  of  the  actin  cytoskeleton  is  essen-
tial  to  migration  and  invasion  of  tumor  cells.63,64 
Five  genes  co-targeted  by  miR-122  and  miR-206 
are  involved  in  this  biological  process,  including 
ARPC3  (actin  related  protein  2/3  complex,  sub-
unit 3, 21 kDa). The ARP2/3 complex is part of the 
“minimum  motility  machine”  that  facilitates  cell 
migration by creating cell protrusions driven through 
actin polymerization.65,66 This multiprotein complex 
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Figure 4. Tabulation of the number of transcripts targeted by each pairwise combination of microRNAs. Transcripts were included in the tabulation if they 
have predicted sites for both microRNAs in the pair. The miR-122/206 pair is predicted to target 174 transcripts, far more than any other pair, and reflects 
the similarity in the seed regions for these two microRNAs. The targeted transcripts are predicted to be regulated by both microRNAs.
5’ 3’
hsa-miR-122
hsa-miR-206
consensus target seed: ACCUUACAUU
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UGGAAUGUAAGGAAG–UGUGUGG
Figure 5. Alignment of miRs 122 and 206 reveals extensive similarity in their seed regions, thereby accounting for the large number of transcripts 
  co-targeted by this pair of microRNAs. Red indicates a perfect match, and yellow indicates an allowable g:U wobble. The ten bases in the 5′ seed region 
are highly conserved.dombkowski et al
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is  necessary  for  the  formation  of  “invadopodia” 
  protrusions that enable metastasizing cancer cells to 
invade the extracellular matrix and migrate into blood 
vessels during intravasation.67–69 Genes critical to the 
minimum  motility  machine  were  found  to  be  dra-
matically up-regulated in invasive breast cancer cells 
that were selected using an in vivo invasion assay.66 
Among this group was the p21 subunit of the ARP2/3 
complex (ARPC3) which was found to be more than 
two-fold up-regulated. Our analysis suggests that the 
motile  nature  of  the  highly  metastatic  breast  cells 
isolated in the Tavazoie work may be facilitated by 
the simultaneous loss of miRs 122 and 206 which 
are  predicted  to  coordinately  repress  a  number  of 
genes involved in regulation of the actin cytoskel-
eton, including ARPC3. The loss of just one of these 
microRNAs  may  not  be  sufficient  to  significantly 
increase the level of transcripts which have both sites 
if sustained levels of the alternative microRNA are 
present. However, coincident loss of both microRNAs 
could result in a critical loss of post-transcriptional 
repression.
Thymosin  beta  4  (TMSB4X)  is  a  regulator  of 
actin  polymerization  and  has  been  implicated  in 
tumor  metastasis  and  cell  motility.  The  TMSB4X 
transcript contains target sites for both miRs 122 and 
206. A dramatic increase of invasiveness and motility 
has been observed in response to   overexpression of 
TMSB4X in SW480 colon cancer cells.70 The same 
report also noted increased expression of TMSB4X 
in human liver metastases as compared to matched 
  primary  colorectal  adenocarcinoma  samples. 
  Elevated expression of TMSB4X was correlated with 
metastatic potential in malignant mouse fibrosarcoma 
cells.71  Additionally,  TMSB4X  expression    levels 
were  found  to  be  elevated  in  metastatic  human 
  melanoma cells, and overexpression was associated 
with increased tumor growth and lung metastases in a 
mouse melanoma model.72,73
Figure 4 reveals that the combination of miR-126 
with any one of the other five microRNAs results 
in very few predicted targets having sites for both 
miRs. This appears to be due to the overall scarcity 
of miR-126 targets found throughout the genome. In 
the MicroCosm Targets database there are 212 human 
transcripts having at least one site with minimum score 
of 15.0 for miR-126. This compares to 976   targets 
for miR-335, 938 for miR-206, 1012 for   miR-489, 
and  1091  for  miR-199a-3p.  Despite  the  relatively 
small set of target genes for miR-126, the loss of this 
microRNA appears to play a role in the metastasis of 
breast cancer. Tavazoie et al reported that the major-
ity  of  primary  tumors  from  breast  cancer  patients 
who relapsed demonstrated a loss of   expression for 
miR-126.18  Investigating  potential  combinatorial 
activity  of  miR-126,  an  important  target  emerged 
from  our  computational  analysis:  RANKL.  This 
gene codes for a member of the tumor necrosis fac-
tor (TNF) cytokine family and is known to induce 
osteoclast activity.74 Increased levels of RANKL have 
been associated with bone metastasis in a variety of 
cancers, and RANKL is actively being pursued as 
a therapeutic target.75–79 A recent study of renal cell 
carcinoma suggests that RANKL may be involved 
in metastasis to sites other than bone by stimulating 
cancer cell migration.80 Another study demonstrated 
that RANKL induced breast and prostate cancer cell 
migration.81 There are conflicting reports regarding 
RANKL  expression  in  MDA-MB-231  cells.  Some 
reports  indicate  that  MDA-MB-231  cells  alone  in 
culture do not express RANKL but can induce RANKL 
expression through cell-cell contact with osteoblastic 
or stromal cells.82,83 However, a recent report found 
basal expression and secretion of RANKL in MDA-
MB-231 cells using ELISA assays.84 It is currently 
unknown if microRNAs influence RANKL expres-
sion in tumor cells. Here, we find that four of the six 
Tavazoie microRNAs (miRs-126, 199a-3p, 335, 489) 
are predicted to target RANKL. Loss of expression 
for this collective set of microRNAs may result in 
RANKL  dysregulation  and  over-expression.  Addi-
tional investigations of RANKL regulation by these 
microRNAs are warranted.
Predicted microRNA activity  
is consistent with previously  
reported gene expression changes  
for PdgFA and KRT81
Since one of the modes of microRNA   activity can 
produce  changes  in  expression  levels  of    target 
transcripts  it  is  of  interest  to  examine  available 
expression data for predicted target genes. In miR-AT! 
we included an option to integrate gene expression 
data alongside microRNA target transcript   predictions. 
The option is available in the results page following 
submission of a set of microRNAs and allows for Combinatorial microRNAs in breast cancer metastasis
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import of a text file containing gene identifiers in the 
first column and quantitative expression values in the 
second  column. The  gene  identifiers  can  be  either 
NCBI Entrez or Ensembl identifiers. The quantitative 
values may be a ratio, fold change, or log ratio repre-
senting a change in transcript abundance.
In  an  earlier  microarray  report  from  the  same 
laboratory  that  performed  the  Tavazoie  et  al 
microRNA  study,  a  set  of  differentially  expressed 
genes  was  identified  in  derivative  MDA-MB-
231 cells that   produce aggressive lung metastases.85 
Supplementary  Table  2  from  that  publication 
provides gene expression changes for a select sub-
set of genes identified as differentially expressed and 
having a minimum 3-fold change when comparing 
lung  metastatic  LM2  derivative  cells  and  parental 
MDA-MB-231 cells. Since the same derivative cells 
were also used in the Tavazoie microRNA study we 
investigated if any of the predicted targets of the six 
down-regulated microRNAs were over-expressed in 
the highly metastatic derivatives, indicating poten-
tial microRNA activity at the transcriptional level. 
We cross referenced the Affymetrix probe identifiers 
from the supplemental table to Entrez Gene IDs using 
DAVID and created a tabular file with the Entrez IDs 
and reported fold changes. This file was imported into 
miR-AT! on the results page using the “Expression” 
button. The subsequent results displayed in miR-AT! 
revealed  predicted  targets  with  a  corresponding 
expression change.
Several predicted target genes were over-expressed 
in the lung metastatic derivative cells, including PDGFA 
(platelet derived growth factor alpha polypeptide) and 
KRT81 (keratin, hair, basic 1; KRTHB1). The genes 
had 5.02 and 6.34-fold increased mRNA expression 
respectively in the highly metastatic cells as compared 
to parental cells (Minn et al Supplementary Table 2).85 
Since these transcripts are also predicted to be targets 
of the repressed Tavazoie microRNAs, which were 
identified using the same cell lines, the evidence col-
lectively suggest the increase in transcript level may 
be due to the loss of the microRNAs. PDGFA has one 
predicted miR-206 target site and two miR-122 sites, 
and is classified in the cell cycle control and cytoskel-
eton  organization  ontologies.  PDGFA  is  expressed 
more frequently in breast tumors than in non-  tumor 
breast tissue and also much more frequently in   primary 
tumors with lymph node metastasis than in tumors 
from patients without metastasis.86 Elevated plasma 
levels of PDGF are correlated with decreased survival 
times of breast cancer patients and a greater extent of 
metastatic involvement.87,88 Inhibition of PDGF recep-
tor signaling reduced tumor growth of human breast 
cancer cells implanted into mouse bone.89
The  KRT81  gene  encodes  for  a  hair  keratin 
  protein  and  has  predicted  sites  for  miRs  335  and 
206.  This  gene  is  normally  expressed  in  the  hair 
follicle; however, a 5′-truncated form of this gene 
(hHb1-∆N) was found to be expressed in metastatic 
and primary breast carcinomas and is notably absent 
in non-  malignant cells.90 Over-expression of the trun-
cated form was also reported in four Epstein-Barr 
virus infected   epithelial carcinoma cell lines.91 Using 
  several  breast  cancer  cell  lines,  it  was    determined 
that the truncated form of the gene was transcribed 
through an alternative promoter located in the fourth 
intron of the gene.92 The authors demonstrated that 
the  protein  product  of  hHb1-∆N  participates  in 
cytoskeleton  structure,  and  they  suggested  that  it 
may  alter  the  adhesive  properties  of  cancer  cells. 
Collectively, the previous reports from the Massague 
lab indicate that KRT81 gene expression was signifi-
cantly elevated in both lung and bone metastatic cell 
derivates that were also used in the microRNA study. 
On the Affymetrix microarrays employed in the asso-
ciated gene expression studies, the probe set targeting 
this gene (213711_at) hybridizes within exon 9 and 
would therefore   measure expression of the full length 
and truncated transcripts. It is intriguing to consider 
that the reported increase of KRT81 messenger RNA 
  levels in highly metastatic MDA-MB-231 cells reflects 
expression of the truncated transcript associated with 
malignancies. Since the truncation occurs at the 5′ 
end, it is expected that predicted microRNA bind-
ing sites for miRs 335 and 206 in the 3′ UTR would 
remain intact in hHb1-∆N. Consequently, loss of these 
microRNAs may contribute to the over-  expression of 
the truncated transcript which may affect cell adhe-
sion in breast malignancies.
Discussion
Microarray  and  next  generation  sequencing  tech-
nologies  have  enabled  high-throughput  analysis  of 
microRNA expression profiles associated with disease 
progression. Numerous studies have found multiple 
microRNAs concurrently dysregulated in a variety of dombkowski et al
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diseases. In these investigations,   microarray assays 
are  often  followed  by  computational  analysis  to 
identify putative target genes of aberrant microRNAs. 
To date, most computational work has focused on 
individual  microRNA-target  interactions.  However, 
recent  reports  have  demonstrated  cooperative  and 
synergistic  activity  among  microRNAs.  Therefore, 
it  is  imperative  to  consider  combinatorial  activity 
when predicting the effect of multiple dysregulated 
microRNAs.
In  this  report  we  introduced  a  web-based  tool, 
miR-AT!,  that  enables  computational  analysis  of 
combinatorial  microRNA  activity.  The  application 
provides the ability to perform fully integrated path-
way and ontology analysis of predicted target genes. 
Additionally,  miR-AT!  provides  novel  features  for 
combinatorial analysis and clustering of transcripts 
using  target  site  patterns.  We  applied  miR-AT!  to 
predict  target  interactions  of  six  microRNAs  that 
have been implicated in breast cancer metastasis.18 
While  the  loss  of  individual  microRNAs  among 
this set may contribute towards metastatic progres-
sion,  the    consistent  loss  of  the  six  microRNAs  as 
a  group  in  highly  metastatic  MDA-MB-231  cell 
derivatives    suggests  that  cooperative  activity  may 
be involved in the aggressive behavior of these cells. 
Our in silico analysis identified numerous predicted 
combinatorial target genes previously implicated in 
cancer metastasis. The loss of only one of multiple 
microRNAs targeting a gene may not incur complete 
loss of suppression of the target, but coincident loss 
of multiple microRNAs could result in more dramatic 
changes in target transcript and/or protein levels.
Our analysis revealed that miR-122 and miR-206 
are predicted to cooperatively target a large set of genes 
due to considerable similarity in their seed regions. 
The set of co-targeted transcripts is enriched for genes 
involved in cytoskeleton regulation and cell adhesion. 
The two microRNAs appear to   function in tandem 
and perhaps offer a level of regulatory redundancy. 
Coincident loss of both microRNAs is predicted to 
result in extensive target gene   dysregulation affecting 
cytoskeleton regulation and cell adhesion.
The  metastatic  spread  of  malignant  cells  is  a 
  complex  process  involving  a  number  of  steps, 
  including local invasion, intravasation, extravasation, 
and remote colonization. These steps require dynamic 
activity in a range of cellular processes, and   several 
are  crucial  to  metastatic  progression.  A  systems 
biology analysis of multiple cancer datasets identified 
cell cycle regulation, cytoskeletal organization, cell 
motility, antigen presentation, and energy metabolism 
as key processes perturbed in all metastatic tumors 
regardless of the primary tissue type.93 Our analysis 
revealed that the genes collectively targeted by the six 
microRNAs are significantly enriched for transcripts 
involved in the first three of these processes and thus 
may cooperatively contribute to the metastatic pro-
gression of breast cancer through the deregulation of 
these pathways. We also used cell network analysis 
to identify central signaling nodes downstream of the 
collective set of predicted target genes. The highest 
scoring nodes were cyclin D1 and c-Myc, indicating 
that the coincident loss of the six microRNAs may 
have a focal effect on these two important regulatory 
nodes, both implicated in oncogenesis and metastasis. 
These  findings  are  consistent  with  observations 
that microRNAs play a vital role in regulating key 
pathways involved in metastasis.94,95
Our  computational  approach  is  a  hypothesis 
generating  method  that  enables  the  exploration  of 
combinatorial microRNA activity. We have identified 
genes  and  cellular  processes  implicated  in  cancer 
metastasis that are predicted to be collective targets 
of the six dysregulated microRNAs. While beyond 
the  scope  of  this  report,  additional  investigations 
to    characterize  and  validate  these  interactions  are 
  warranted. It is important to note that the   predictions 
are  based  on  computational  models  and  potential 
false  positives  must  be  considered.  However,  our 
focus on target genes having multiple, high-scoring 
microRNA binding sites is expected to diminish false 
positives. Previously reported laboratory validation 
of some microRNA-target interactions identified in 
our analysis also provides confidence in the approach 
and the underlying prediction method.
Cooperative microRNA activity is likely an integral 
component of most cell regulatory networks, and the 
analysis of combinatorial effects may be of benefit in 
the development of miR-based   therapeutic   strategies. 
Both  anti-miR  and  miR  replacement  approaches 
show  promise,  with  the  latter  being  of  particular 
interest in cancer treatment since a   number of   studies 
have reported extensive repression of microRNAs in 
tumors.96 Combinatorial targeting may provide greater 
efficacy in repressing hyperactivated   pathways than Combinatorial microRNAs in breast cancer metastasis
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that which could be obtained through the use of a 
single microRNA.
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